Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25938574 | 0.76 | GABRA1 (0.33) | GABRA1GABRB1KDM4ELMNA | |
| SCHEMBL25938628 | 0.73 | PPARA (0.32) | KDM4E | |
| SCHEMBL25928173 | 0.72 | KDM4E (0.31) | KDM4ELMNA | |
| SCHEMBL25938570 | 0.72 | GABRA1 (0.33) | GABRA1GABRB1LMNA | |
| SCHEMBL25928172 | 0.69 | HPGD (0.32) | POLBKDM4E | |
| SCHEMBL19475121 | 0.69 | GABRA1 (0.41) | GABRA1GABRB1 | |
| SCHEMBL21789250 | 0.68 | KDM4E (0.33) | POLBKDM4ELMNA | |
| SCHEMBL12263282 | 0.68 | CCR1 (0.37) | GABRA1GABRB1KDM4ELMNA | |
| SCHEMBL24287673 | 0.68 | BACE1 (0.35) | GABRA1GABRB1POLBGAAGFER | |
| SCHEMBL20681209 | 0.68 | GABRA1 (0.33) | GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | GABRA1 4210/4885GABRB1 4052/4885POLB 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.